Anebulo Pharma reports Q4 FY2024 net loss $0.05/share; net loss down 48% YoY; awarded $1.9M NIDA grant

Anebulo Pharmaceuticals, Inc.

Q4 FY2024 net loss $1.3M ($0.05/sh) vs $2.5M ($0.10/sh) in Q4 FY2023.
Full-year FY2024 net loss $8.2M ($0.32/sh) vs $11.7M ($0.47/sh) in FY2023.
Cash and equivalents $3.1M at June 30, 2024; additional $10M available under loan agreement.
Awarded up to $1.9M NIDA grant for IND-enabling activities for IV selonabant for pediatric cannabis poisoning.
Expects to enroll first healthy volunteer in H1 2025 for IV formulation clinical study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.